This paper explores a simulation model of the evolution of the pharmaceutical industry, focusing on the factors that influence entry and survival. Indeed, one major puzzle in the interpretation of the history of pharmaceuticals concerns why entry has not been a relevant feature of this industry - especially as it concerns the innovative core and until the advent of the biotechnology revolution - despite low cumulativeness in the process of drug discovery and low levels of concentration. In particular, the paper studies the implications on market structure and innovation of alternative patterns of entry, in terms of number of entrants and timing of entry.

Garavaglia, C., Malerba, F., & Orsenigo, L. (2006). Entry, market structure and innovation in a history-friendly model of the evolution of the pharmaceutical industry. In Knowledge accumulation and industry evolution: the case of Pharma-Biotech (pp. 234-265). Cambridge University Press.

Entry, market structure and innovation in a history-friendly model of the evolution of the pharmaceutical industry

Garavaglia, C;
2006

Abstract

This paper explores a simulation model of the evolution of the pharmaceutical industry, focusing on the factors that influence entry and survival. Indeed, one major puzzle in the interpretation of the history of pharmaceuticals concerns why entry has not been a relevant feature of this industry - especially as it concerns the innovative core and until the advent of the biotechnology revolution - despite low cumulativeness in the process of drug discovery and low levels of concentration. In particular, the paper studies the implications on market structure and innovation of alternative patterns of entry, in terms of number of entrants and timing of entry.
No
Scientifica
Capitolo o saggio
industrial dynamics, history-friendly models, pharmaceuticals, entry;
English
Knowledge accumulation and industry evolution: the case of Pharma-Biotech
9780521858229
Garavaglia, C., Malerba, F., & Orsenigo, L. (2006). Entry, market structure and innovation in a history-friendly model of the evolution of the pharmaceutical industry. In Knowledge accumulation and industry evolution: the case of Pharma-Biotech (pp. 234-265). Cambridge University Press.
Garavaglia, C; Malerba, F; Orsenigo, L
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/1265
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 7
Social impact